Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
Naranie Shanmuganathan(South Australia Pathology), Timothy P. Hughes(South Australia Pathology), Haley Altamura(South Australia Pathology), Sa-Hee Park(Leukemia Research Foundation), David M. Ross(South Australia Pathology), Jodi Braley(South Australia Pathology), Devendra Hiwase(Australasian Leukaemia and Lymphoma Group), Ilaria S. Pagani(South Australian Health and Medical Research Institute), Agnes S. M. Yong(South Australia Pathology), David T Yeung(South Australia Pathology), Dong‐Wook Kim(Catholic University of Korea), Susan Branford(Centre for Cancer Biology)
Cited by 86
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464